Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.69 |
| ▸ | PTGES | O14684 | 1/20 | 0.66 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.64 |
| ▸ | NT5E | P21589 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | TOP2A | P11388 | 1/20 | 0.64 |
| ▸ | RELA | Q04206 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 4/20 | 0.62 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14388723 | 1.00 | CETP (0.69) | CETPPTGESPRKCDPTPN1NT5E | |
| SCHEMBL5798459 | 1.00 | CETP (0.69) | CETPPTGESPRKCDPTPN1NT5E | |
| SCHEMBL14110309 | 1.00 | CETP (0.69) | CETPPTGESPRKCDPTPN1NT5E | |
| SCHEMBL14191491 | 0.98 | CETP (0.71) | CETPPTGESPRKCDPTPN1NT5E | |
| SCHEMBL5800321 | 0.95 | CETP (0.63) | CETPPTGESPRKCDPTPN1NT5E | |
| SCHEMBL5800555 | 0.93 | CETP (0.61) | CETPPTGESPRKCDPTPN1NT5E | |
| SCHEMBL14108321 | 0.93 | CETP (0.68) | CETPPTGESPRKCDPTPN1NT5E | |
| SCHEMBL1867184 | 0.92 | CETP (0.81) | CETPPTGESPRKCDPTPN1NT5E | |
| SCHEMBL22571027 | 0.90 | CETP (0.70) | CETPPTGESPRKCDPTPN1NT5E | |
| SCHEMBL554507 | 0.90 | PRKCD (0.80) | CETPPTGESPRKCDPTPN1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008280-B2 | Betulinol derivatives as anti-HIV agents | BIORINGS LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-20080286291-A1 | Betulinol Derivatives as Anti-Hiv Agents | SAXENA RESEARCH, LLC | 2008-11-20 | — | — | US | disclosed |
| EP-1786433-A4 | BETULINOL DERIVATIVES AS ANTI-HIV AGENTS | SAXENA BRIJ B (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1786433-A2 | BETULINOL DERIVATIVES AS ANTI-HIV AGENTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060154904-A1 | Betulinol derivatives as anti-HIV agents | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2006031706-A2 | BETULINOL DERIVATIVES AS ANTI-HIV AGENTS | CORNELL RESEARCH FOUNDATION, INC (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060019934-A1 | Anti-HIV-1 activity of betulinol derivatives | SAXENA, BRIJ B. | 2006-01-26 | — | — | US | disclosed |
| WO-2005112929-A2 | ANTI-HIV-1 ACTIVITY OF BETULINOL DERIVATIVES | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-6890533-B2 | Betulinol derivatives | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-0988311-B9 | BETULINOL DERIVATIVES | CORNELL RES FOUNDATION INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1473301-A2 | Betulinol derivatives | CORNELL RESEARCH FOUNDATION, INC. (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-0988311-B1 | BETULINOL DERIVATIVES | CORNELL RES FOUNDATION INC (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040001837-A1 | Anticancer complex | BOMSHTEYN, ARKADIY | 2004-01-01 | — | — | US | disclosed |
| US-20030036540-A1 | Betulinol derivatives | BOMSHTEYN, ARKADIY | 2003-02-20 | — | — | US | disclosed |
| EP-0988311-A4 | BETULINOL DERIVATIVES | CORNELL RES FOUNDATION INC (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-0988311-A1 | BETULINOL DERIVATIVES | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998055497-A1 | BETULINOL DERIVATIVES | CORNELL RESEARCH FOUNDATION, INC. (US) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019934-A1 | Anti-HIV-1 activity of betulinol derivatives | BET1, NFATC1, CD4 | CETP 2054/4885PTGES 3365/4885PRKCD 3063/4885 |
| US-20060154904-A1 | Betulinol derivatives as anti-HIV agents | BET1, NFATC1, CD4 | CETP 2054/4885PTGES 3919/4885PRKCD 3512/4885 |
| US-20080286291-A1 | Betulinol Derivatives as Anti-Hiv Agents | BET1, NFATC1, CD4 | CETP 2054/4885PTGES 3919/4885PRKCD 3512/4885 |
| US-20040001837-A1 | Anticancer complex | BET1, TMPO, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CETP 2356/4885PTGES 3909/4885PRKCD 4109/4885 |
| US-20030036540-A1 | Betulinol derivatives | BET1, TMPO, HRH3 | CETP 1962/4885PTGES 3283/4885PRKCD 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.